A Safer, Stable Alternative to Universal CAR T Cells

To address limitations in autologous CAR T cell therapy, Spanish researchers have developed a strategy using CRISPR-Cas9 to create universal anti-CD19 CAR T cells with a defined memory phenotype. This approach reduces graft-versus-host and host-versus-graft responses by targeting B2M and TRAC genes and utilises less differentiated T cells for improved stability and persistence.

By: Gorm Palmgren - May. 30, 2024

In the study, CRISPR-Cas9 technology was employed to generate CAR T cells, which were then subjected to CRISPRroots transcriptome analysis to confirm effective gene knockout and ensure no unintended off-target effects. The generated universal CAR T cells demonstrated potent lytic activity against tumour cells while exhibiting a reduced cytokine secretion profile. These findings were validated through comprehensive in vitro experiments.

This innovative method, which uses the CRISPRroots pipeline to enhance the reliability and safety of gene editing, holds the potential to produce more stable and persistent CAR T cells with reduced adverse effects compared to traditional autologous CAR T cell therapies. The study emphasises the importance of a defined memory phenotype in the stability and efficacy of CAR T cell treatments.

The study was led by Karim Benabdellah, who is affiliated with Pfizer-University of Granada-Andalusian Regional Government Centre for Genomics and Oncological Research (GENYO), Granada, Spain. It was published yesterday in Frontiers in Immunology.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagCMN BriefsHashtagNews

News: A Safer, Stable Alternative to Universal CAR T Cells
News: A Safer, Stable Alternative to Universal CAR T Cells
CLINICAL TRIALS
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine